Innovent stock heads toward ESMO data after strong first half

Published on 10/07/2026 at 06:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Innovent stock was at HKD 97.45 on October 7, 2026, down 1.91 percent. First-half revenue rose 44.8 percent to CNY 8.618 billion as ESMO data approach.

Innovent, KYG4818G1010, Illustration mit AI erstellt.

Innovent stock (ISIN KYG4818G1010) was trading at HKD 97.45 on the Hong Kong Stock Exchange on October 7, 2026 at 11:59 a.m. HKT, down 1.91 percent from the previous close. The next major company checkpoint is a clinical-data presentation at the ESMO Annual Meeting beginning October 23, 2026.

ESMO creates a clear catalyst

According to PR Newswire on September 23, 2026, Innovent will present data on IBI343, IBI363, IBI3001, IBI354 and TYVYT at ESMO in Madrid from October 23 to October 27, 2026.

The most prominent item is a late-breaking oral presentation of the Phase 3 G-HOPE-001 trial for IBI343 in previously treated gastric or gastroesophageal junction cancer. The program has reached a pivotal evidence point, but the release provides a schedule rather than efficacy results.

Revenue and profit accelerate

In first-half 2026, revenue reached CNY 8.618 billion, a 44.8 percent year-over-year increase, according to Futubull on September 18, 2026. Product revenue rose 56.7 percent to CNY 8.201 billion, showing that commercial medicines remained the main growth engine.

Net profit increased 50.2 percent year over year to CNY 1.253 billion, while non-IFRS profit rose 40.5 percent to CNY 1.704 billion. The combination of revenue growth and profit expansion gives the upcoming clinical disclosures greater financial relevance than a pipeline update alone.

Consensus stays above the market

According to Markets Insider on September 24, 2026, the published consensus rating was Strong Buy with an average price target of HKD 132.78; Bernstein maintained Buy with a HKD 128.00 target on September 22, 2026.

Using the October 7 price of HKD 97.45, the consensus target lies 36.25 percent above the market price. That gap reflects the value investors assign to commercial growth and late-stage programs, while clinical execution remains the key counter-factor.

Stock stays below yearly high

Innovent's October 7 market capitalization was HKD 169.7 billion, with volume of 2,164,302 shares. The HKD 97.45 price stood 13.53 percent below the 52-week high of HKD 112.70 and above the 52-week low of HKD 69.55.